Euro-celtique S.a.

Cocensys Inc.

Warner-lambert Company

Purdue Neuroscience Company

Other

University of Southern California

Nancy C Lan

Sui Xiong Cai

Yan Wang

Eckard Weber

John F W Keana

Christopher Franklin Bigge

David B Fick

Richard Woodward

Anthony P Guzikowski

Zhang-Lin Zhou

John F Keana

Jonathan L Wright

Ravindra B Upasani

George Field

Derk J Hogenkamp

Ravi Upasani

Kelvin W Gee

Michael B Bolger

Victor I Ilyin

Seid Mirsadeghi

Christopher S Konkoy

Delia Belelli

Po-wai Yuen

Gian Luca Araldi

Suzanne Ross Kesten

Haiji Xia

John Fw Keana

Donald Lamunyon

Soo Hong-Bae

Robert Purdy

Syed Hasan Tahir

Robert H Purdy

The invention is directed to substituted 2-aminoacetamides represented by formula (II): and to pharmaceutically acceptable salts and prodrugs thereof, wherein the substituents are defined herein. The invention is also directed to the use of substituted 2-aminoacetamides in methods for the treatment of neuronal damage following global and focal ischemia, and for the treatment, prevention or amelioration of pain, anxiety, or manic depression, as anticonvulsants, as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

Substituted 2-aminoacetamides and the use thereof

The invention is directed to substituted-aminoacetamides represented by formula (II): and to pharmaceutically acceptable salts and prodrugs thereof, wherein the substituents are defined herein. The invention is also directed to the use of substituted-aminoacetamides in methods for the treatment of neuronal damage following global and focal ischemia, and for the treatment, prevention or amelioration of pain, as anticonvulsants, as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.

Substituted 1(2H)-phthalazinones and pharmaceutical compositions thereof

The invention is directed to substituted 2-aminoacetamides represented by formula (II): and to pharmaceutically acceptable salts and prodrugs thereof, wherein the substituents are defined herein. The invention is also directed to the use of substituted 2-aminoacetamides in methods for the treatment of neuronal damage following global and focal ischemia, and for the treatment, prevention or amelioration of pain, as anticonvulsants, as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

Methods of treating or preventing chronic pain or convulsion are disclosed by administering to an animal a sodium channel blocker and at least one of gabapentin and pregabalin. Also disclosed are pharmaceutical compositions and kits for the treatment or prevention of chronic pain or convulsion.

Sodium channel blocker compositions and the use thereof

The invention is directed to substituted 2-aminoacetamides represented by formula (II): and to pharmaceutically acceptable salts thereof, wherein the substituents are defined herein, for use in the treatment or amelioration of pain.

Substituted 5-oxo-5, 6, 7, 8-tetrahydro-4H-1-benzopyrans

Neuroactive steroids of the androstane and pregnane series

Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof

Substituted 5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of AMPA

Novel 2-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 2-substituted piperidine analogs as selectively active antagonist of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headaches, chronics pain, glaucoma, CMV retinitis, psychosis, urinary incontinence, opioid tolerance or withdrawal, or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described.

2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists

The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, Parkinson's disease, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

Subtype-selective NMDA receptor ligands and the use thereof

Growing community of inventors

South Pasadena, CA, United States of America

Nancy C Lan